Roche is launching a new global phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys in ...
Eli Lilly is wasting no time in pursuit of the next indication for its newly christened obesity pill Foundayo, presenting new ...
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as Olixir New York ...
The FDA’s Pharmacy Compounding Advisory Committee will meet this summer to discuss if certain peptides from compounding ...
Apart from Daiichi, a growing number of drugmakers have elected to part ways with their over-the-counter businesses in recent ...
Despite a new supply commitment from Gilead Sciences, Doctors Without Borders/Médecins Sans Frontières (MSF) is poking holes ...
AI heavyweight Anthropic has appointed Novartis CEO Vas Narasimhan to its board of directors as the link between the ...
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
For Astellas’ chief manufacturing officer Rao Mantri, Ph.D.—who entered the position a little over a year ago—production is ...
Actress, producer, and artist Lucy Liu has joined Pfizer’s mission to deliver a knockout blow against cancer, becoming the ...
As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting ...
Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results